Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease

Frontiers in Neuroendocrinology

Volumn 33, Issue 2, 2012, Pages 169-178

  Bourque, Mélanie ^a,b   Dluzen, Dean E ^c   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Northeastern Ohio Medical University   (United States)

Author keywords

Akt; ERK; Estradiol; Estrogen receptor; MPTP; Neuroprotection; SERMs; Signaling; Striatum; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4,4",4" [4 PROPYL [1H] PYRAZOLE 1,3,5 TRIYL]TRIS PHENOL; ALPHA TOCOPHEROL; ANDROSTENEDIOL; DIARYLPROPIONITRILE; ESTRADIOL; ESTRADIOL BENZOATE; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHYTOESTROGEN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN KINASE B; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

CELL INTERACTION; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ESTROGEN ACTIVITY; GLIA CELL; HUMAN; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ESTROGENS; GONADAL STEROID HORMONES; HUMANS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION;

EID: 84862305294     PISSN: 00913022     EISSN: 10956808     Source Type: Journal    
DOI: 10.1016/j.yfrne.2012.02.003     Document Type: Review

References (136)

1. Abdelhamid R., Luo J., Vandevrede L., Kundu I., Michalsen B., Litosh V.A., Schiefer I.T., Gherezghiher T., Yao P., Qin Z., Thatcher G.R. Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism. ACS Chem. Neurosci. 2011, 2:256-268.
2. Al-Sweidi S., Morissette M., Bourque M., Di Paolo T. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease. Neuropharmacology 2011, 61:583-591.
3. Al Sweidi S., Sanchez M.G., Bourque M., Morissette M., Dluzen D., Di Paolo T. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease. J. Neuroendocrinol. 2012, 24:48-61.
4. Arevalo M.A., Diz-Chaves Y., Santos-Galindo M., Bellini M.J., Garcia-Segura L.M. Selective oestrogen receptor modulators decrease the inflammatory response of glial cells. J. Neuroendocrinol. 2012, 24:183-190.
5. Arevalo M.A., Santos-Galindo M., Bellini M.J., Azcoitia I., Garcia-Segura L.M. Actions of estrogens on glial cells: implications for neuroprotection. Biochim. Biophys. Acta 1800, 2010:1106-1112.
6. Azcoitia I., Santos-Galindo M., Arevalo M.A., Garcia-Segura L.M. Role of astroglia in the neuroplastic and neuroprotective actions of estradiol. Eur. J. Neurosci. 2010, 32:1995-2002.
7. Azcoitia I., Sierra A., Garcia-Segura L.M. Neuroprotective effects of estradiol in the adult rat hippocampus: interaction with insulin-like growth factor-I signalling. J. Neurosci. Res. 1999, 58:815-822.
8. Baba Y., Putzke J.D., Whaley N.R., Wszolek Z.K., Uitti R.J. Gender and the Parkinson's disease phenotype. J. Neurol. 2005, 252:1201-1205.
9. Bains M., Cousins J.C., Roberts J.L. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp. Neurol. 2007, 204:767-776.
10. Baluchnejadmojarad T., Roghani M., Nadoushan M.R., Bagheri M. Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phytother. Res. 2009, 23:132-135.
11. Baraka A.M., Korish A.A., Soliman G.A., Kamal H. The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's disease. Life Sci. 2011, 88:879-885.
12. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol. 2009, 30:142-157.
13. Bourque M., Liu B., Dluzen D.E., Di Paolo T. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity. Biochem. Pharmacol. 2007, 74:1413-1423.
14. Bourque M., Liu B., Dluzen D.E., Di Paolo T. Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways. Psychoneuroendocrinology 2011, 36:955-969.
15. Brailoiu E., Dun S.L., Brailoiu G.C., Mizuo K., Sklar L.A., Oprea T.I., Prossnitz E.R., Dun N.J. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J. Endocrinol. 2007, 193:311-321.
16. Brinton R.D. Requirements of a brain selective estrogen: advances and remaining challenges for developing a NeuroSERM. J. Alzheimers Dis. 2004, 6:S27-S35.
17. Bywood P.T., Johnson S.M. Dendrite loss is a characteristic early indicator of toxin-induced neurodegeneration in rat midbrain slices. Exp. Neurol. 2000, 161:306-316.
18. Callier S., Morissette M., Grandbois M., Pelaprat D., Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001, 41:131-138.
19. Cardona-Gomez G.P., DonCarlos L., Garcia-Segura L.M. Insulin-like growth factor I receptors and estrogen receptors colocalize in female rat brain. Neuroscience 2000, 99:751-760.
20. Cardona-Gomez G.P., Mendez P., Garcia-Segura L.M. Synergistic interaction of estradiol and insulin-like growth factor-I in the activation of PI3K/Akt signaling in the adult rat hypothalamus. Brain Res. Mol. Brain Res. 2002, 107:80-88.
21. Cartharius K., Frech K., Grote K., Klocke B., Haltmeier M., Klingenhoff A., Frisch M., Bayerlein M., Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21:2933-2942.
22. Cerciat M., Unkila M., Garcia-Segura L.M., Arevalo M.A. Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia 2010, 58:93-102.
23. Creutz L.M., Kritzer M.F. Mesostriatal and mesolimbic projections of midbrain neurons immunoreactive for estrogen receptor beta or androgen receptors in rats. J. Comp. Neurol. 2004, 476:348-362.
24. Currie L.J., Harrison M.B., Trugman J.M., Bennett J.P., Wooten G.F. Postmenopausal estrogen use affects risk for Parkinson disease. Arch. Neurol. 2004, 61:886-888.
25. D'Astous M., Mendez P., Morissette M., Garcia-Segura L.M., Di Paolo T. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol. Pharmacol. 2006, 69:1492-1498.
26. D'Astous M., Mickley K.R., Dluzen D.E., Di Paolo T. Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice. Neuroendocrinology 2005, 82:111-120.
27. D'Astous M., Morissette M., Di Paolo T. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 2004, 47:1180-1188.
28. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
29. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psych. Res. 1979, 1:249-254.
30. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252.
31. Dewing P., Boulware M.I., Sinchak K., Christensen A., Mermelstein P.G., Micevych P. Membrane estrogen receptor-alpha interactions with metabotropic glutamate receptor 1a modulate female sexual receptivity in rats. J. Neurosci. 2007, 27:9294-9300.
32. Dhandapani K.M., Wade F.M., Mahesh V.B., Brann D.W. Astrocyte-derived transforming growth factor-{beta} mediates the neuroprotective effects of 17{beta}-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology 2005, 146:2749-2759.
33. Di Paolo T., Rouillard C., Bedard P. 17 beta-Estradiol at a physiological dose acutely increases dopamine turnover in rat brain. Eur. J. Pharmacol. 1985, 117:197-203.
34. Do Rego J.L., Seong J.Y., Burel D., Leprince J., Luu-The V., Tsutsui K., Tonon M.C., Pelletier G., Vaudry H. Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front. Neuroendocrinol. 2009, 30:259-301.
35. Du B., Ohmichi M., Takahashi K., Kawagoe J., Ohshima C., Igarashi H., Mori-Abe A., Saitoh M., Ohta T., Ohishi A., Doshida M., Tezuka N., Takahashi T., Kurachi H. Both estrogen and raloxifene protect against beta-amyloid-induced neurotoxicity in estrogen receptor alpha-transfected PC12 cells by activation of telomerase activity via Akt cascade. J. Endocrinol. 2004, 183:605-615.
36. Dubal D.B., Rau S.W., Shughrue P.J., Zhu H., Yu J., Cashion A.B., Suzuki S., Gerhold L.M., Bottner M.B., Dubal S.B., Merchanthaler I., Kindy M.S., Wise P.M. Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ERalpha in estradiol-mediated protection against delayed cell death. Endocrinology 2006, 147:3076-3084.
37. Duka T., Duka V., Joyce J.N., Sidhu A. Alpha-synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 2009, 23:2820-2830.
38. Funakoshi T., Yanai A., Shinoda K., Kawano M.M., Mizukami Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem. Biophys. Res. Commun. 2006, 346:904-910.
39. Gao F., Ma X., Ostmann A.B., Das S.K. GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERalpha) phosphorylation signals. Endocrinology 2011, 152:1434-1447.
40. Garcia-Segura L.M. Aromatase in the brain: not just for reproduction anymore. J. Neuroendocrinol. 2008, 20:705-712.
41. Garcia-Segura L.M., Arevalo M.A., Azcoitia I. Interactions of estradiol and insulin-like growth factor-I signalling in the nervous system: new advances. Prog. Brain Res. 2010, 181:251-272.
42. Gingerich S., Kim G.L., Chalmers J.A., Koletar M.M., Wang X., Wang Y., Belsham D.D. Estrogen receptor alpha and G-protein coupled receptor 30 mediate the neuroprotective effects of 17beta-estradiol in novel murine hippocampal cell models. Neuroscience 2010, 170:54-66.
43. Goekoop R., Duschek E.J., Knol D.L., Barkhof F., Netelenbos C., Scheltens P., Rombouts S.A. Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. Neuroimage 2005, 25:63-75.
44. Grandbois M., Morissette M., Callier S., Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 2000, 11:343-346.
45. Grove-Strawser D., Boulware M.I., Mermelstein P.G. Membrane estrogen receptors activate the metabotropic glutamate receptors mGluR5 and mGluR3 to bidirectionally regulate CREB phosphorylation in female rat striatal neurons. Neuroscience 2010, 170:1045-1055.
46. Guillot T.S., Miller G.W. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 2009, 39:149-170.
47. Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J., Leenders K.L., Eshuis S., Booij J., Dluzen D.E., Horstink M.W. Gender differences in Parkinson's disease. J. Neurol. Neurosurg. Psych. 2007, 78:819-824.
48. Hazell G.G., Yao S.T., Roper J.A., Prossnitz E.R., O'Carroll A.M., Lolait S.J. Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J. Endocrinol. 2009, 202:223-236.
49. Hetman M., Gozdz A. Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur. J. Biochem. 2004, 271:2050-2055.
50. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia - normal and in Parkinson's disease. J. Chem. Neuroanat. 2001, 22:3-12.
51. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., Rakic P., Flavell R.A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:665-670.
52. Inestrosa N.C., Arenas E. Emerging roles of Wnts in the adult nervous system. Nat. Rev. Neurosci. 2010, 11:77-86.
53. Ivanova T., Mendez P., Garcia-Segura L.M., Beyer C. Rapid stimulation of the PI3-kinase/Akt signalling pathway in developing midbrain neurones by oestrogen. J. Neuroendocrinol. 2002, 14:73-79.
54. Jourdain S., Morissette M., Morin N., Di Paolo T. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J. Neuroendocrinol. 2005, 17:509-517.
55. Kompoliti K., Comella C.L., Jaglin J.A., Leurgans S., Raman R., Goetz C.G. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology 2000, 55:1572-1575.
56. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-870.
57. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139:4252-4263.
58. Kumar P., Wu Q., Chambliss K.L., Yuhanna I.S., Mumby S.M., Mineo C., Tall G.G., Shaul P.W. Direct Interactions with G alpha i and G betagamma mediate nongenomic signaling by estrogen receptor alpha. Mol. Endocrinol. 2007, 21:1370-1380.
59. Kuo J., Hamid N., Bondar G., Prossnitz E.R., Micevych P. Membrane estrogen receptors stimulate intracellular calcium release and progesterone synthesis in hypothalamic astrocytes. J. Neurosci. 2010, 30:12950-12957.
60. Kwok J.B., Hallupp M., Loy C.T., Chan D.K., Woo J., Mellick G.D., Buchanan D.D., Silburn P.A., Halliday G.M., Schofield P.R. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 2005, 58:829-839.
61. L'Episcopo F., Serapide M.F., Tirolo C., Testa N., Caniglia S., Morale M.C., Pluchino S., Marchetti B. A Wnt1 regulated Frizzled-1/beta-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: therapeutical relevance for neuron survival and neuroprotection. Mol. Neurodegener. 2011, 6:49.
62. L'Episcopo F., Tirolo C., Testa N., Caniglia S., Morale M.C., Cossetti C., D'Adamo P., Zardini E., Andreoni L., Ihekwaba A.E., Serra P.A., Franciotta D., Martino G., Pluchino S., Marchetti B. Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol. Dis. 2011, 41:508-527.
63. L'Episcopo F., Tirolo C., Testa N., Caniglia S., Morale M.C., Marchetti B. Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol. Disord. Drug Targets 2010, 9:349-372.
64. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
65. Lebesgue D., Traub M., De Butte-Smith M., Chen C., Zukin R.S., Kelly M.J., Etgen A.M. Acute administration of non-classical estrogen receptor agonists attenuates ischemia-induced hippocampal neuron loss in middle-aged female rats. PLoS One 2010, 5:e8642.
66. Lee E.S., Sidoryk M., Jiang H., Yin Z., Aschner M. Estrogen and tamoxifen reverse manganese-induced glutamate transporter impairment in astrocytes. J. Neurochem. 2009, 110:530-544.
67. Lee E.S., Yin Z., Milatovic D., Jiang H., Aschner M. Estrogen and tamoxifen protect against Mn-induced toxicity in rat cortical primary cultures of neurons and astrocytes. Toxicol. Sci. 2009, 110:156-167.
68. Levin E.R. G protein-coupled receptor 30: estrogen receptor or collaborator?. Endocrinology 2009, 150:1563-1565.
69. Li X.L., Cheng W.D., Li J., Guo X.L., Guo C.J., Meng X.H., Sun S.G., Wang L.X. Protective effect of estrogen on apoptosis in a cell culture model of Parkinson's disease. Clin. Invest Med. 2008, 31:E258-E264.
70. Lin C.M., Lin R.D., Chen S.T., Lin Y.P., Chiu W.T., Lin J.W., Hsu F.L., Lee M.H. Neurocytoprotective effects of the bioactive constituents of Pueraria thomsonii in 6-hydroxydopamine (6-OHDA)-treated nerve growth factor (NGF)-differentiated PC12 cells. Phytochemistry 2010, 71:2147-2156.
71. Liu B., Dluzen D.E. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin. Exp. Pharmacol. Physiol. 2007, 34:555-565.
72. Liu L.X., Chen W.F., Xie J.X., Wong M.S. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci. Res. 2008, 60:156-161.
73. Lyons K.E., Hubble J.P., Troster A.I., Pahwa R., Koller W.C. Gender differences in Parkinson's disease. Clin. Neuropharmacol. 1998, 21:118-121.
74. Malagelada C., Jin Z.H., Greene L.A. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J. Neurosci. 2008, 28:14363-14371.
75. Malagelada C., Ryu E.J., Biswas S.C., Jackson-Lewis V., Greene L.A. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J. Neurosci. 2006, 26:9996-10005.
76. Marino M., Galluzzo P., Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genomics 2006, 7:497-508.
77. Matsuda K., Sakamoto H., Mori H., Hosokawa K., Kawamura A., Itose M., Nishi M., Prossnitz E.R., Kawata M. Expression and intracellular distribution of the G protein-coupled receptor 30 in rat hippocampal formation. Neurosci. Lett. 2008, 441:94-99.
78. McArthur S., Murray H.E., Dhankot A., Dexter D.T., Gillies G.E. Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition. J. Neurochem. 2007, 100:678-692.
79. Mendez P., Azcoitia I., Garcia-Segura L.M. Estrogen receptor alpha forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain. Brain Res. Mol. Brain Res. 2003, 112:170-176.
80. Mermelstein P.G., Becker J.B., Surmeier D.J. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J. Neurosci. 1996, 16:595-604.
81. Miller D.B., Ali S.F., O'Callaghan J.P., Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. N. Y. Acad. Sci. 1998, 844:153-165.
82. Mitra S.W., Hoskin E., Yudkovitz J., Pear L., Wilkinson H.A., Hayashi S., Pfaff D.W., Ogawa S., Rohrer S.P., Schaeffer J.M., McEwen B.S., Alves S.E. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 2003, 144:2055-2067.
83. Morale M.C., L'Episcopo F., Tirolo C., Giaquinta G., Caniglia S., Testa N., Arcieri P., Serra P.A., Lupo G., Alberghina M., Harada N., Honda S., Panzica G.C., Marchetti B. Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?. Brain Res. Rev. 2008, 57:431-443.
84. Morale M.C., Serra P.A., L'Episcopo F., Tirolo C., Caniglia S., Testa N., Gennuso F., Giaquinta G., Rocchitta G., Desole M.S., Miele E., Marchetti B. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 2006, 138:869-878.
85. Morissette M., Al Sweidi S., Callier S., Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol. Cell Endocrinol. 2008, 290:60-69.
86. Morissette M., Jourdain S., Al Sweidi S., Menniti F.S., Ramirez A.D., Di Paolo T. Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology 2007, 52:1509-1520.
87. Nilsson S., Koehler K.F., Gustafsson J.A. Development of subtype-selective oestrogen receptor-based therapeutics. Nat. Rev. Drug Discov. 2011, 10:778-792.
88. Obeso J.A., Marin C., Rodriguez-Oroz C., Blesa J., Benitez-Temino B., Mena-Segovia J., Rodriguez M., Olanow C.W. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann. Neurol. 2008, 64(Suppl. 2):S30-S46.
89. Otto C., Fuchs I., Kauselmann G., Kern H., Zevnik B., Andreasen P., Schwarz G., Altmann H., Klewer M., Schoor M., Vonk R., Fritzemeier K.H. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol. Reprod. 2009, 80:34-41.
90. Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., Langer G., Bader B., Prelle K., Nubbemeyer R., Fritzemeier K.H. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 2008, 149:4846-4856.
91. Parcellier A., Tintignac L.A., Zhuravleva E., Hemmings B.A. PKB and the mitochondria: AKTing on apoptosis. Cell Signal. 2008, 20:21-30.
92. Pawlak J., Karolczak M., Krust A., Chambon P., Beyer C. Estrogen receptor-alpha is associated with the plasma membrane of astrocytes and coupled to the MAP/Src-kinase pathway. Glia 2005, 50:270-275.
93. Pedram A., Razandi M., Levin E.R. Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol. 2006, 20:1996-2009.
94. Perillo B., Sasso A., Abbondanza C., Palumbo G. 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol. Cell Biol. 2000, 20:2890-2901.
95. Petit-Paitel A., Brau F., Cazareth J., Chabry J. Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One 2009, 4:e5491.
96. Pike C.J. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease. J. Neurochem. 1999, 72:1552-1563.
97. Popat R.A., Van Den Eeden S.K., Tanner C.M., McGuire V., Bernstein A.L., Bloch D.A., Leimpeter A., Nelson L.M. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005, 65:383-390.
98. Prossnitz E.R., Barton M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostagl. Other Lipid Mediat. 2009, 89:89-97.
99. Prossnitz E.R., Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol. 2011, 7:715-726.
100. Quesada A., Lee B.Y., Micevych P.E. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev. Neurobiol. 2008, 68:632-644.
101. Quesada A., Micevych P.E. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J. Neurosci. Res. 2004, 75:107-116.
102. Quesada A., Romeo H.E., Micevych P. Distribution and localization patterns of estrogen receptor-beta and insulin-like growth factor-1 receptors in neurons and glial cells of the female rat substantia nigra: localization of ERbeta and IGF-1R in substantia nigra. J. Comp. Neurol. 2007, 503:198-208.
103. Quintanilla R.A., Munoz F.J., Metcalfe M.J., Hitschfeld M., Olivares G., Godoy J.A., Inestrosa N.C. Trolox and 17beta-estradiol protect against amyloid beta-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway. J. Biol. Chem. 2005, 280:11615-11625.
104. Ragonese P., D'Amelio M., Salemi G., Aridon P., Gammino M., Epifanio A., Morgante L., Savettieri G. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 2004, 62:2010-2014.
105. Raz L., Khan M.M., Mahesh V.B., Vadlamudi R.K., Brann D.W. Rapid estrogen signaling in the brain. Neurosignals 2008, 16:140-153.
106. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625-1630.
107. Robottom B.J., Mullins R.J., Shulman L.M. Pregnancy in Parkinson's disease: case report and discussion. Expert Rev. Neurother. 2008, 8:1799-1805.
108. Rodriguez-Navarro J.A., Solano R.M., Casarejos M.J., Gomez A., Perucho J., de Yebenes J.G., Mena M.A. Gender differences and estrogen effects in parkin null mice. J. Neurochem. 2008, 106:2143-2157.
109. Rubin S.M. Parkinson's disease in women. Dis. Mon. 2007, 53:206-213.
110. Sanchez M.G., Bourque M., Morissette M., Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 2010, 16:e43-e71.
111. Sanchez M.G., Morissette M., Di Paolo T. Effect of a chronic treatment with 17beta-estradiol on striatal dopamine neurotransmission and the Akt/GSK3 signaling pathway in the brain of ovariectomized monkeys. Psychoneuroendocrinology 2012, 37:280-291.
112. R. Saunders-Pullman, C. Derby, N. Santoro, S. Bressman, B. Chiu, R.B. Lipton, S. Wassertheil-Smoller, Role of endogenous and exogenous hormone exposure on the risk of Parkinson disease, in: Annual meeting of American Academy of Neurology. Abstract S23.002, Seattle, Washington, 2009.
113. Saunders-Pullman R., Gordon-Elliott J., Parides M., Fahn S., Saunders H.R., Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999, 52:1417-1421.
114. Sawada H., Ibi M., Kihara T., Honda K., Nakamizo T., Kanki R., Nakanishi M., Sakka N., Akaike A., Shimohama S. Estradiol protects dopaminergic neurons in a MPP+Parkinson's disease model. Neuropharmacology 2002, 42:1056-1064.
115. Schultz K.N., von Esenwein S.A., Hu M., Bennett A.L., Kennedy R.T., Musatov S., Toran-Allerand C.D., Kaplitt M.G., Young L.J., Becker J.B. Viral vector-mediated overexpression of estrogen receptor-alpha in striatum enhances the estradiol-induced motor activity in female rats and estradiol-modulated GABA release. J. Neurosci. 2009, 29:1897-1903.
116. Sharma K., Mehra R.D. Long-term administration of estrogen or tamoxifen to ovariectomized rats affords neuroprotection to hippocampal neurons by modulating the expression of Bcl-2 and Bax. Brain Res. 2008, 1204:1-15.
117. Sharma K., Mehra R.D., Dhar P., Vij U. Chronic exposure to estrogen and tamoxifen regulates synaptophysin and phosphorylated cAMP response element-binding (CREB) protein expression in CA1 of ovariectomized rat hippocampus. Brain Res. 2007, 1132:10-19.
118. Shughrue P.J. Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta). Exp. Neurol. 2004, 190:468-477.
119. Simpkins J.W., Wen Y., Perez E., Yang S., Wang X. Role of nonfeminizing estrogens in brain protection from cerebral ischemia: an animal model of Alzheimer's disease neuropathology. Ann. N. Y. Acad. Sci. 2005, 1052:233-242.
120. Singh M., Setalo G., Guan X., Warren M., Toran-Allerand C.D. Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J. Neurosci. 1999, 19:1179-1188.
121. Sotnikova T.D., Beaulieu J.M., Gainetdinov R.R., Caron M.G. Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol. Disord. Drug Targets 2006, 5:45-56.
122. Strijks E., Kremer J.A., Horstink M.W. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin. Neuropharmacol. 1999, 22:93-97.
123. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37:510-518.
124. Taylor H.S., Manson J.E. Update in hormone therapy use in menopause. J. Clin. Endocrinol. Metab. 2011, 96:255-264.
125. Thomas P., Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J. Steroid Biochem. Mol. Biol. 2006, 102:175-179.
126. Thomas P., Pang Y., Filardo E.J., Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146:624-632.
127. Tolson D., Fleming V., Schartau E. Coping with menstruation: understanding the needs of women with Parkinson's disease. J. Adv. Nurs. 2002, 40:513-521.
128. Twelves D., Perkins K.S., Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov. Disord. 2003, 18:19-31.
129. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003, 157:1015-1022.
130. Wang S., Ren P., Li X., Guan Y., Zhang Y.A. 17beta-Estradiol protects dopaminergic neurons in organotypic slice of mesencephalon by MAPK-mediated activation of anti-apoptosis gene BCL2. J. Mol. Neurosci. 2011, 45:236-245.
131. Wooten G.F., Currie L.J., Bovbjerg V.E., Lee J.K., Patrie J. Are men at greater risk for Parkinson's disease than women?. J. Neurol. Neurosurg. Psych. 2004, 75:637-639.
132. Xiromerisiou G., Hadjigeorgiou G.M., Papadimitriou A., Katsarogiannis E., Gourbali V., Singleton A.B. Association between AKT1 gene and Parkinson's disease: a protective haplotype. Neurosci. Lett. 2008, 436:232-234.
133. Yi K.D., Perez E., Yang S., Liu R., Covey D.F., Simpkins J.W. The assessment of non-feminizing estrogens for use in neuroprotection. Brain Res. 2011, 1379:61-70.
134. Zhang Q.G., Wang R., Khan M., Mahesh V., Brann D.W. Role of Dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation. J. Neurosci. 2008, 28:8430-8441.
135. Zhao L., Jin C., Mao Z., Gopinathan M.B., Rehder K., Brinton R.D. Design, synthesis, and estrogenic activity of a novel estrogen receptor modulator - a hybrid structure of 17beta-estradiol and vitamin E in hippocampal neurons. J. Med. Chem. 2007, 50:4471-4481.
136. Zhao L., O'Neill K., Diaz Brinton R. Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Brain Res. Rev. 2005, 49:472-493.